Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2016
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Mar 2013 Planned end date changed from 1 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 02 Dec 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.